A Phase II study to assess the safety and efficacy of TGR-1202 in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy

Protocol: 
AAAQ8698
Phase: 
II

A Phase II study to assess the safety and efficacy of TGR-1202 in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy

This study is being done to see how well tolerated the investigational drug TGR-1202 is in comparison to other similar therapeutics agents.

Are you Eligible? (Inclusion Criteria)

- Confirmed diagnosis of CLL
- CLL warranting therapy as per investigator discretion
- 18 years of age or older

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States